Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Polaris, Arch provide $15mm Series A financing to deCODE spin-off NextCODE Health

Executive Summary

NextCODE Health LLC, a firm focused on diagnosing genetic diseases, launched with $15mm in Series A funding from Polaris Partners and Arch Venture Partners. The start-up, a spin-off of Icelandic company deCODE genetics EHF (a division of Amgen Inc.), is beginning operations with an exclusive five-year license to deCODE’s technology related to sequence-based clinical diagnostics. NextCODE will use the new money to scale the integration of its genomics services into clinical markets.
Deal Industry
  • In Vitro Diagnostics
  • Research, Analytical Equipment & Supplies
  • Services
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Biotechnology
    • Drug Discovery Tools
      • Bioinformatics
Deal Status
  • Final
Deal Type
  • Financing
    • Spin-Off
    • Venture Financing

Related Companies